Abstract
Background Cannabis use (CA) and childhood trauma (CT) independently increase the risk of earlier psychosis onset; but their interaction in relation to psychosis risk and association with endocannabinoid-receptor rich brain regions, i.e. the hippocampus (HP), remains unclear. The objective was to determine whether lower age of psychosis onset (AgePsyOnset) is associated with CA and CT through mediation by the HP, and genetic risk, as measured by schizophrenia polygene scores (SZ-PGRS).
Methods Cross- sectional, case-control, multicenter sample from 5 metropolitan US regions. Participants (n=1185) included 397 controls not affected by psychosis (HC); 209 participants with bipolar disorder type-1; 279 with schizoaffective disorder; and 300 with schizophrenia (DSM IV-TR). CT was assessed using the Childhood Trauma Questionnaire (CTQ); CA was assessed by self-reports and trained clinical interviewers. Assessment included neuroimaging, symptomatology, cognition and calculation of the SZ polygenic risk score (SZ-PGRS).
Outcomes In survival analysis, low CT and CA are associated with lower AgePsyOnset. At high CT or CA, CT or CA are individually sufficient to affect AgePsyOnset. CT relation with AgePsyOnset is mediated in part by the HP in CA users before AgePsyOnset. CA before AgePsyOnset is associated with higher SZ-PGRS and correlated with younger age at CA usage.
Interpretation CA and CT interact to increase risk when moderate; while severe CT and/or CA abuse/dependence are each sufficient to affect AgePsyOnset, indicating a ceiling effect. Probands with/out CA before AgePsyOnset differ on biological variables, suggesting divergent pathways to psychosis.
Funding MH077945; MH096942; MH096913; MH077862; MH103368; MH096900; MH122759.
Evidence before this study Cannabis use (CA) and childhood trauma (CT) independently increase the risk of earlier development of psychosis. Scarce evidence exists on the interaction between CA and CT and the neurobiological substrate of their interaction.
Added value of this study Analysis of a large transdiagnostic sample of psychosis probands and controls (N=1288) indicates synergy of CT and CA and small but significant contribution of the posterior hippocampus. Data further indicate existence of two populations of probands with psychosis, those with and those without CA after CT before psychosis onset. CT and CA before psychosis onset interact according to a stepwise increase up to reaching a ceiling effect.
Implications of all the available evidence Clinically, youth with low, medium CT need to be targeted for intervention before CA onset.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Grant Support The study was supported by MH077945 Dr. Pearlson; MH096942 to Dr. Keshavan; MH096913 to Dr. Tamminga; MH077862 to Dr. Sweeney; MH103368 to Dr. Gershon; MH096900 to Dr. Clementz; and by MH122759 to Dr. del Re.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Each Institution involved in the study gave ethical approval for this work. The Institutions are: Harvard Medical School, University of Chicago, University of Texas Southwestern Medical Center, Rosalind Franklin University, University of Georgia, Yale University, University of Cincinnati.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Revision of manuscript with added analyses
Data Availability
All data produced in the present study are available upon reasonable request to the authors
